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Background: Little is known about the functional relationship of delaying second-line treatment 
initiation for HIV-positive patients and mortality, given a patient’s immune status.  
 
Methods: We included 7255 patients starting antiretroviral therapy between 2004-2017, from 9 South 
African cohorts, with virological failure and complete baseline data. We estimated the impact of switch 
time on the hazard of death using inverse probability of treatment weighting (IPTW) of marginal 
structural models. The non-linear relationship between month of switch and the 5-year survival 
probability, stratified by CD4 count at failure, was estimated with targeted maximum likelihood 
estimation (TMLE). We adjusted for measured time-varying confounding by CD4 count, viral load and 
visit frequency.  
 
Results: 5-year mortality was estimated as 10.5% (2.2%; 18.8%) for immediate switch and as 26.6% 
(20.9%; 32.3%) for no switch (49.9% if CD4 count<100 cells/mm3). The hazard of death was estimated to 
be 0.40 (95%CI: 0.33-0.48) times lower if everyone had been switched immediately compared to never. 
The shorter the delay in switching, the lower the hazard of death, e.g. delaying 30-60 days reduced the 
hazard 0.52 (0.41-0.65) times, and 60-120 days 0.56 (0.47-0.66) times.  
 
Conclusions: Early treatment switch is particularly important for patients with low CD4 counts at failure. 





Anti-retroviral treatment (ART) was received by an estimated 4.4 million (61%) people living with HIV in 
South Africa in 20171. As the number of HIV-positive patients with access to ART has increased, so has 
the number of patients that have experienced failure of first-line ART. Patients with virological failure on 
first-line ART should, in principle, switch to second-line therapy as soon as possible, as a delay in 
switching treatment regimens has been shown to lead to increased mortality 2-7. South African 
guidelines recommend switching from two nucleoside reverse transcriptase inhibitors (NRTIs) and one 
non-nucleoside reverse transcriptase inhibitor (NNRTI) to two NRTIs and one protease inhibitor (PI) if 
two consecutive viral loads on first line therapy are greater than 1000 copies/mL.  However, in resource 
limited settings it is still common to delay the switch 8-10. Reasons for delays include doubts about 
adequate patient adherence, availability of viral load testing and the cost of second line regimens11,12.  
The effect of delayed switch to second-line therapy on mortality has been investigated in several 
observational studies which adjusted for measured time-varying confounders using causal inference 
methods. Gsponer et al. 5 showed the drastic reduction in mortality for patients switching to second-line 
compared to no switch based on an immunological criteria of failing, as well as the benefit of switching 
early. Petersen et al.6  estimated the effect of delayed switch after confirmed virological failure on 
survival and quantified the relative benefit of earlier switch based on the assumption of a linear 
relationship between timing of switch and probability of death. Other studies have looked into the 
impact of delayed switch in South Africa7, the effect of using different viral failure definitions2 and the 
relative efficacy of various monitoring strategies4. 
There have been few studies which have explored the functional relationship between time of switch 
and mortality13, and there is potential for further research into whether there may be a “breaking point” 
beyond which further delays could be particularly risky, especially for patients with an already 
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compromised immune system. In particular, it would be of interest to know whether the effect of 
delayed switch is modified by CD4 count at failure. Previous studies have looked at this, albeit in 
different contexts6,7. Moreover, from a programmatic perspective there may also be a benefit to 
minimising the time between first viral load greater than 1000 copies/mL and switch given that with 
new technologies like resistance testing, patients with adequate adherence and proven resistance could 
potentially be switched earlier. In addition, most of the studies to date had relatively small patient 
numbers and limited follow-up times.  
Our study aims at addressing these gaps. We assess the impact of delayed switch from first-line ART 
treatment to second-line ART treatment on mortality in 9 South African treatment programs; a large 
cohort with long follow-up. We use two related but distinct causal approaches; inverse probability of 
treatment weighting (IPTW) and targeted maximum likelihood estimation (TMLE), which allow us to 
present or findings on the hazard and incidence scales. The impact of delayed switch is flexibly modelled 
for patients with different disease severities based on CD4 count at time of viral load failure. We also 
investigate the importance of monitoring the delay between the first viral load (VL) measure over 1000 
copies/ml and confirmed failure (second VL measure >1000 copies /ml) as part of the delay in switch on 
mortality outcomes. 
Methods 
Study setting and definitions 
We included 9 HIV treatment facilities in Southern Africa that took part in the IeDEA-SA collaboration 
(http://www.iedeasa.org/), namely Desmond Tutu HIV Centre Gugulethu, Hlabisa HIV Treatment and 
Care Programme, Tygerberg, McCord Hospital, 3 treatment facilities at the Khayelitsha ART Programme, 
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Themba Lethu Clinic and Masiphumelele Clinic. The collaboration has been described in detail elsewhere 
14.  
Adult patients who that started treatment on a first-line treatment regime (2 NRTIs + 1 NNRTI) and 
failed first-line therapy after 1st January 2004, were included in the analysis. Failure was defined as two 
consecutive VL measurements greater than 1000 copies/mL and measured at least 4 weeks apart. If 
measures were taken less than 4 weeks apart the next measure was considered. We excluded patients 
without any record of receiving ART, those that experienced virological failure within 6 months of ART 
initiation, those that were not receiving ART at the time of first VL failure and those that switched before 
viral load failure.  In total, we included 7255 patients for the main complete case analysis, see Figure 1, 
and 8008 patients in the sensitivity analysis with multiple imputation for missing baseline data. Earliest 
entry date into our sample was 4th October 2004 and the database was closed on 16th August 2017. 
In the main analysis, baseline was defined at the time of first-line viral failure i.e. the date at which the 
second of the two consecutive viral loads were over 1000 copies per/ml. A secondary analysis was 
performed using the date at which the first of the two consecutive VLs was greater than 1000 copies 
per/mL as the baseline, which represents the earliest indication of viral failure. The sample of patients 
was the same regardless of the definition used because only patients with two elevated viral loads were 
included. A switch from first-line ART to second-line ART was broadly defined as a switch from 2 NRTIs 
and 1 NNRTI to 2 NRTIs and 1 PI. A detailed list of second-line regimens in our data is provided in 
Supplementary Table 1. Patients were defined as being lost to follow-up if there was no visit or event for 
9 months after their last recorded visit and before database closure.  
The primary endpoint was mortality which was recorded through clinic’s patient files and updated 
through data from the South African national vital registry where available (this approach is expected to 




Analysis time started at the date of first-line failure, defined as 2 VL>1000 copies/mL in the main analysis 
and 1 VL>1000 in the secondary analysis, as described above. Our primary exposure was the timing of 
switch to second-line ART, measured in months since the respective date of failure and we used this to 
assess the effect on both the hazard of death and 5-year survival.  
Measured and included baseline characteristics (at time of confirmed failure) are age, sex, highest and 
lowest CD4 count prior to failure, highest and lowest log VL measure prior to failure, an indicator 
whether a patient was ever suppressed prior to failure, WHO clinical stage at time of ART initiation, year 
of ART start and treatment facility. Time-varying variables which potentially determined the decision to 
switch as well as mortality, and were affected by prior treatment regimes, were CD4 count, VL and 
treatment frequency (measured as number of visits within the past 6 months). It is possible to adjust for 
confounding of these variables using appropriate causal inference methods 16. 
We estimated the effect of timing of switch on the hazard of death using inverse probability of 
treatment weighting (IPTW) of marginal structural models 2. To estimate the effect of treatment switch, 
as well as the non-linear relationship between month since failure and month of switch on the 
probability of 5-year mortality, stratified by CD4 count at failure, we used targeted maximum likelihood 
estimation (TMLE) for longitudinal marginal structural working models 17. 
 
For IPTW, we used 7 different switching delay strategies; no switch and delayed switch by <30 days, 30-
59 days, 60-119 days, 120-179 days, 180-359 days, and ≥ 360 days. We created 7 clones/replicates per 
patient, one for each treatment strategy, as described previously 7. A clone/replicate is censored after it 
ceases to follow the respective switching strategy. The remaining uncensored observations were 
weighted to represent what would have happened if the censored patients had continued to follow the 
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respective switching strategy. We used pooled logistic regression models weighted by the stabilized 
inverse probabilities of treatment and censoring to estimate the effect of the different strategies on the 
hazard of death. The logistic regression models used to derive the weights contained the above-
mentioned time-dependent and baseline variables in the denominator, and baseline variables only in 
the numerator. The Supplementary Material (Supplementary table 5, Technical Appendix) contains a 
detailed description of implementation of the method and model specifications. In sensitivity analyses, 
missing baseline CD4 count and WHO stage were imputed using multiple imputation by chained 
equations18. 
With TMLE, we first estimated 5-year mortality under immediate switch after confirmed failure and no 
switch using the R-package ltmle 19. The iterated outcome regressions, i.e. the relationship between 
mortality and the covariates at each point in time (based on 3-month intervals) were estimated using 
super learning. Super learning is a data-adaptive approach that combines different modelling 
approaches, such as logistic regression or other regression approaches, such that the expected 
prediction error (estimated via cross validation) is minimized, see the technical appendix 
(Supplementary Material) for more details. We then specified marginal structural working models to 
model the relationship between month since failure, month of switching, and survival, conditional on 
CD4 count at failure; see technical appendix and the footnote in Figure 3 for more details. The fitted 
models, calculated based on the approach described in Petersen et al. 17, were then used to visualize the 
relationship. 
 





This IeDEA-SA collaboration study was approved by the University of Cape Town and University of Bern 
human research ethics committees. At most sites, the requirement for informed consent was waived, as 




Median time from ART start to failure was 1218 days (about 3.3 years); median time from confirmed 
failure to switch was 121 days (1st quartile: 49 days; 3rd quartile: 288 days), with follow-up times from 
confirmed failure ranging between 1 and 4409 days (median 1835 days, IQR 1183-2470). During follow-
up 3765 patients (52%) switched, and 842 (12%) died.  
The included patients were mostly female (65%), and had advanced WHO stage at ART initiation (60%), 
see Table 1. Among patients that never switched, a substantial proportion (19%) had a viral load 
>100.000 copies/mL at confirmed viral load failure.  
The probability of being switched was higher among patients with low current CD4 count, high VL, and a 
higher visit frequency (Table 2). These variables also predicted the probability of death, confirming that 
they are likely time-varying confounders.  
The effect of immediate switch compared to no switch on mortality, if confirmed failure was used as 
failure definition, was estimated as 0.49 (95% CI: 0.42-0.58) in a crude analysis, and as 0.37 (0.30-0.46) 
using IPTW. Results with multiple imputation were 0.47 (0.40-0.54) in a crude analysis, and 0.36 (0.30-
0.44) using IPTW. If first VL>1000 copies/mL was used as definition of failure the estimates were 0.52 
(0.45-0.61) and 0.42 (0.34-0.52) respectively. After imputation the results were 0.50 (0.43-0.58) and 0.41 
(0.34-0.51) (Supplementary Table 2). Figure 2 shows that the shorter the delay in switching, the lower 
the hazard of death. There are stronger benefits of early switch when considering one VL>1000 
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copies/mL as failure definition. Similar results are obtained after multiple imputation of baseline CD4 
count and WHO stage (Supplementary Table 2). Sensitivity analyses show that truncation of the 
stabilized weights at the 1st and 99th quantile yields the most stable results (Supplementary Table 3).  
Using TMLE, 5-year mortality was estimated as 10.5% (2.2%; 18.8%) if everyone had been switched 
immediately, and as 26.6% (20.9%; 32.3%) if everyone had stayed on their failing regimen. The 
corresponding risk difference was -16.1% (-26.1%; -6.1%), and the odds ratio was 0.32 (0.13; 0.82). The 
working MSM’s, fitted with TMLE, are visualized in Figure 3. The black dashed line shows that the 
estimated 5-year mortality (i.e. 60 months after failure) to be about 25% under no switching (month of 
switch = 60). However, this varies considerably by immune status at failure. Almost 51% would have 
died among those who had a CD4 count <100 at failure (red line), but only a small proportion (17.5%) 
among those with a CD4 count > 200 cells/mm3 (green line). Moreover, the effect of delaying treatment 
was more severe (i.e. steeper ascent) among patients failing with CD4 count < 100 cells/mm3. Similar 
results are obtained when evaluating probabilities of death <5 years (Supplementary Figure 1). Overall, 
the estimated relationship between switch time and mortality was non-linear, as visualized in Figure 3. 
This is because the estimated coefficients of the non-linear switch time terms in the working MSMs 
were important, and also significant at the 5% level. 
Discussion 
Statement of principal findings 
Our study highlights that it often takes a long time to switch patients to second line treatment in 
Southern Africa. We have shown that an early switch of regimen is highly beneficial in terms of reduced 
mortality. Patients with low CD4 counts at time of failure are at particularly high risk of increased 




Strengths and limitations  
Our study is based on a large data set, with a multitude of different treatment regimens and long follow-
up, which allowed us to model the relationships in the data in a flexible and robust way. Since our 
patients have relatively regular viral load measurements for the setting, we have been able to evaluate 
the effect of switching based on viral failure, rather than immunological failure; which is of great interest 
given that viral load monitoring is typically not available in public sector programs in resource limited 
settings, though it is currently being expanded. Another strength is the use of causal inference methods 
to adjust for time-dependent confounding affected by prior treatment, which would not be possible 
with traditional regression analyses 16. This helped us to contrast switching strategies under different 
viral failure definitions. We also used TMLE, which has desirable statistical properties (double 
robustness), to confirm and extend the MSM analysis. In contrast to previous studies, we have even 
been able to implement this method for a marginal structural model that postulated non-linear 
relationships between treatment strategies and survival.  
Our study has some limitations. Our analysis is based on routine data from South African treatment 
programs. It may well be possible that patients defined to be lost to follow-up are in fact cycling in and 
out of care, possibly in different provinces  22; or that the complication of capturing start and stop dates 
of different drugs may lead to inaccuracies that could potentially also affect our ability to accurately 
define switch dates. The diagnostics further suggested that there could be some positivity violations in 
our data which means that individuals may not have a positive probability of continuing to receive 
treatment according to a specific treatment rule, given that they have done so thus far and irrespective 
of the covariate history (Supplementary Table 4, Supplementary Figure 2). This could have affected our 
estimates. Another limitation is the unavailability of patient-level adherence data. 
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There are additional limitations associated with the first VL>1000 at baseline (secondary) analysis, which 
occur due to the definition of the sample. Eligibility for the sample is based on confirmed failure. After 
first VL>1000, those included cannot switch or die until after their next VL measurement, thus creating a 
period of immortal time. Table 1 indicates that the period of time between first VL>1000 and confirmed 
failure is greater, on average, for those with longer delays between confirmed failure and switch. Hence, 
this may cause some bias in the comparisons of delay strategies. Furthermore, the restriction of the first 
VL>1000 sample to patients that attained confirmed failure (VL>1000) at next VL measurement means 
that the secondary analysis can only be interpreted in reference to the confirmed-failure population, 
and therefore is not generalizable to the wider population.  
Interpretation of findings 
It is no surprise that delayed treatment switch may affect patient’s health. However, according to our 
results, earlier switch is of particular benefit when switching after the first sign of failure, i.e. the first 
viral load > 1000 copies/mL, for those that go on to confirmed failure. HIV specialists may be reluctant to 
switch patients that have adherence problems or are unstable, but for stable patients who fail because 
of resistance or toxicities, early switching after a first elevated viral load could be of benefit.  
Our results confirm that switching is partly determined by visit frequency, which may relate to clinician 
concern for patients based on health status, but also strongly relates to patient’s engagement in care 
and adherence. To reduce the risk of failure of another regimen, patients on second-line treatment 
should be adherent. We have shown the benefit of switching even under imperfect adherence, but 





Results in context 
Our results comparing immediate switch to no switch yield similar conclusions to other studies which 
used other definitions of failure, which were done in different patient populations, for different follow-
up times, and used different methodological approaches5-7,17. Like Rohr et al.7 we show the that the 
effectiveness of switching strategies depends on disease severity, though in a more refined way given 
that we modelled the relationship non-linearly for different patient groups. Similar to other studies we 
have shown that remaining on first-line therapy leads to an increase in mortality compared to switching, 
and that earlier switch is beneficial in terms of survival 6,17. Our marginal structural working models were 
more complex than the MSMs in these studies, which makes a more refined interpretation of the dose-
response relationship between delay in switching and mortality possible; however, both previous 
studies13 and current research23 suggests that it may be important to allow for even more flexible 
approaches to model specification and fitting than ours. Nevertheless, whatever methodological 
approach is chosen, it is important to note that the beneficial effect of switching can be observed for 
different definitions of treatment failure 5,6. 
Our results have two direct implications for current programme guidance. Firstly, for stable virologically 
suppressed patients, it is no longer recommended in South Africa that they receive regular CD4 counts. 
However, once a patient is viraemic, our results demonstrate the critical importance of CD4 count in 
further risk stratifying patients. The value of dropping routine CD4 count testing in the interests of cost-
saving, needs to be considered alongside the benefits of the additional information it provides on 
disease severity and mortality risk, and could be used to highlight groups that are in more urgent need 
of early switch.  
In patients who subsequently fail virologically, we have demonstrated that the delay between the first 
and second elevated viral load contribute to the non-linear early increase in mortality resulting from 
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delayed switching, especially in patients with low CD4 counts. This points to the importance of either 
accelerating confirmation of virological failure in patients with advanced immunological suppression, or 
to consider switching at the first evidence of viraemia if cost and regimen-sparing are no longer 
important considerations driving the need to confirm virologic failure. 
Further research 
In the South-African context, and according to WHO guidelines, switching is permitted after confirmed 
failure. Hence, our analyses were restricted to a subgroup of patients with 2 consecutive VL>1000. The 
wider dataset, indicated in figure 1, shows that some patients switch onto second-line treatment prior 
to confirmed virologic failure. It would be interesting to investigate the impact of time to switch from 
first elevated VL using a sample defined with the eligibility criteria of one VL>1000. In this larger sample, 
the additional complication of the competing risk of virologic re-suppression would need to be 
considered in the analysis, as re-suppressing patients would no-longer be eligible for switch. 
Conclusions 
Our study highlights the importance of early treatment switch, particularly for patients with low CD4 
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Figure 1: Flow diagram for inclusion of patients in our analysis 
 
 
All adult patients within 9 IeDEA-SA treatment facilities, who 
entered the database after 1st January 2004 
   
N= 113,107 
(ever death= 13,583 (12%)) 
 
 Dropped patients that did not experience viral load (VL) failure 
N= 10,531 
(ever death= 1,299 (12%)) 
 
 
Dropped patients that did not have any recorded ART drug data, or 
experienced VL failure within 6 months of initiation of ART 
N= 9,735 
(ever death= 1,161 (12%)) 
  
Dropped patients that were recorded to start ART treatment after 
VL failure and patients that did not start treatment on a first-line 
regime (2 NRTIs + 1 NNRTI) 
N= 8,830 
(ever death= 1,084 (12%)) 
  Dropped patients who switched prior to first VL measure of 
confirmed VL failure  
N= 8,284 
(ever death= 1,020 (12%)) 
 ever switch N= 3,910 (47%))    
  Dropped patients who switched prior to second VL measure of 
confirmed  VL failure 
N= 8,008 
(ever death= 973 (12%)) 
ever switch N= 3,910 (49%)) 
  Dropped patients who had missing CD4 count at baseline, missing 
WHO stage at baseline and/or missing gender. 
N= 7,255 
(ever death= 842 (12%)) 




Table 1: Characteristics of patients at confirmed viral load failure (second consecutive viral load measure greater than 1000 copies/ml) 
Categories Never switch Switch 0-30 days Switch 30-60 days Switch 60-120 days Switch 120-180 days Switch 180-360 days Switch 360 days Total 
Total 3490 627 619 624 442 701 752 7255 
number of switches 0 (0%) 627 (100%) 619 (100%) 624 (100%) 442 (100%) 701 (100%) 752 (100%) 3765 (52%) 
number of deaths 475 (14%) 61 (10%) 63 (10%) 59 (9%) 46 (10%) 76 (11%) 62 (8%) 842 (12%) 
Gender (female) 2247 (64%) 378 (60%) 420 (68%) 394 (63%) 282 (64%) 471 (67%) 509 (68%) 4701 (65%) 
Age at failure   
         <30 624 (18%) 101 16(%) 124 (20%) 117 (19%) 76 (17%) 144 (21%) 209 28(%) 1395 (19%) 
         >=30 &<40 1611 (46%) 265 (42%) 264 (43%) 293 (47%) 205 (46%) 337 (48%) 344 (46%) 3319 (46%) 
         >40 1255 (36%) 261 (42%) 231 (37%) 214 (34%) 161 (36%) 220 (31%) 199 (26%) 2541 (35%) 
WHO at ART initiation   
         I/II 1334 (38%) 324 (52%) 317 (51%) 263 (42%) 165 (37%) 267 (38%) 228 (30%) 2898 (40%) 
         III/IV 2156 (62%) 303 (48%) 302 (49%) 361 (58%) 277 (63%) 434 (62%) 524 (70%) 4357 (60%) 
CD4 count at failure   
         >0 & <50 337 (10%) 67 (11%) 45 (7%) 45 (7%) 31 (7%) 39 (6%) 37 (5%) 601 (8%) 
         >50 & <100 334 (10%) 56 (9%) 64 (10%) 46 (7%) 34 (8%) 54 (8%) 51 (7%) 639 (9%) 
         >=100 & <200 753 (22%) 151 (24%) 131 (21%) 156 (25%) 124 (28%) 165 (24%) 185 (25%) 1665 (23%) 
         >=200 & <350 1076 (31%) 221 (35%) 211 (34%) 218 (35%) 151 (34%) 262 (37%) 303 (40%) 2442 (34%) 
         >=350 & <500 567 (16%) 77 (12%) 110 (18%) 99 (16%) 61 (14%) 115 (16%) 126 (17%) 1155 (16%) 
         >=500 423 (12%) 55 (9%) 58 (9%) 60 (10%) 41 (9%) 66 (9%) 50 (7%) 753 (10%) 
RNA measure at failure   
         >1000 & <5000 1152 (33%) 154 (25%) 214 (35%) 212 (34%) 159 (36%) 235 (34%) 308 (41%) 2434 (34%) 
         >=5000 & <10000 457 (13%) 97 (25%) 88 (14%) 79 (13%) 69 (16%) 130 (19%) 127 (17%) 1047 (14%) 
         >=10000 & <50000 913 (26%) 199 (32%) 168 (27%) 207 (33%) 121 (27%) 195 (28%) 194 (26%) 1997 (28%) 
         >=50000 & <100000 306 (9%) 62 (10%) 54 (9%) 49 (8%) 44 (10%) 54 (8%) 52 (7%) 621 (9%) 
         >=100000 662 (19%) 115 (18%) 95 (15%) 77 (12%) 49 (11%) 87 (12%) 71 (9%) 1156 (16%) 
RNA suppression prior to failure 2652 (76%) 432 (69%) 436 (70%) 469 (75%) 315 (71%) 534 (76%) 578 (77%) 5416 (75%) 
                 
Median days (IQR)   
time from failure to switch - 28 (21-28) 49 (36-56) 85 (77-106) 145 (132-162) 245 (210-292) 638 (481-940) 121 (49-288) 
time from ART start to failure 1456 (893-165) 1021 (569-1679) 964 (568-1597) 986 (589-1678) 1107 (631-1724) 1064 (696-1728) 1028 (678-1516) 1218 (730-1916) 
time from RNA>1000 to confirmed failure 141(91-257) 84 (56-113) 91 (58-127) 90 (56-136) 112 (78-157) 115 (84-171) 134 (84-185) 115 (83-190) 
time from ART start to last contact 2425(1686-3108) 2762 (1884-3564) 2762 (1811-3447) 2808 (1995-3564) 2929 (2211-3661) 3009 (2266-3665) 3316 (2727-3981) 2688 (1898-3431) 
time from confirmed failure to last contact 592.5 (294-1175) 1435 (777-2080) 1306 (722-2008) 1481 (749-2132) 1538 (1013-21426) 1653 (1087-2109) 2110 (1556-2664) 1095 (481-1885) 
number of CD4A measures from failure to last contact 1 (0-3) 2 (1-5) 3 (1-5) 3 (1-6) 3 (2-6) 4 (2-6) 6 (3-9) 2 (1-5) 




Table 2: Predictors of switch from first-line to second-line ART and predictors of death  
















CD4 cell count, per mm3 
Reference category (>0&<50) 
>=50&<100 0.90 0.38 (0.72-1.14) 0.44 0.00 (0.35-0.55) 
>=100&<200 0.83 0.10 (0.66-1.04) 0.21 0.00 (0.16-0.27) 
>=200&<350 0.82 0.11 (0.65-1.04) 0.13 0.00 (0.10-0.18) 
>=350&<500 0.95 0.71 (0.72-1.25) 0.06 0.00 (0.04-0.09) 
>=500 0.72 0.06 (0.52-1.02) 0.03 0.00 (0.02-0.06) 
 
RNA, copies/ml 
Reference category (>0&<250) 
>=250&<500 0.68 0.21 (0.37-1.24) 1.09 0.69 (0.71-1.68) 
>=500&<1000 2.29 0.00 (1.49-3.54) 1.59 0.06 (0.98-2.57) 
>=1000&<10000 12.56 0.00 (9.26-17.02) 2.40 0.00 (1.73-3.31) 
>=10000&<100000 17.84 0.00 (12.89-24.69) 3.04 0.00 (2.12-4.37) 
>=100000 16.62 0.00 (11.47-24.08) 4.37 0.00 (2.86-6.66) 
 
time-CD4 interaction 1.00 0.04 (1.00-1.00) 1.00 0.25 (1.00-1.00) 
time-RNA interaction 1.00 0.53 (1.00-1.00) 1.00 0.01 (1.00-1.00) 
number of visits within the past 6 months 1.27 0.00 (1.26-1.29) 0.94 0.00 (0.91-0.97) 
 
Baseline 
CD4 cell count, per mm3 
Reference category (>0&<50) 
>=50&<100 1.31 0.04 (1.01-1.69) 1.02 0.88 (0.78-1.34) 
>=100&<200 1.49 0.00 (1.16-1.91) 0.97 0.80 (0.73-1.27) 
>=200&<350 1.70 0.00 (1.30-2.22) 1.05 0.76 (0.77-1.44) 
>=350&<500 1.50 0.01 (1.11-2.04) 1.31 0.18 (0.88-1.95) 
>=500 1.58 0.01 (1.10-2.27) 1.73 0.05 (1.00-3.01) 
 
RNA, copies/ml 
Reference category (>0&<5000) 
>=5000&<10000 1.10 0.07 (0.99-1.22) 0.98 0.88 (0.76-1.27) 
>=10000&<50000 0.92 0.12 (0.82-1.02) 1.13 0.27 (0.91-1.40) 
>=50000&<100000 0.99 0.95 (0.85-1.16) 1.31 0.06 (0.99-1.71) 
>=100000 0.90 0.24 (0.77-1.07) 1.40 0.01 (1.09-1.81) 
 
pre-failure VL suppression 1.03 0.86 (0.71-1.51) 1.23 0.66 (0.48-3.15) 
WHO Stage III/IV at ART initiation 0.91 0.02 (0.85-0.99) 1.18 0.05 (1.00-1.40) 
age  1.00 0.02 (1.00-1.01) 1.02 0.00 (1.01-1.03) 
gender 1.07 0.10 (0.99-1.15) 0.91 0.20 (0.78-1.05) 
Adjusted for follow-up time using restricted cubic splines. Other controls include pre-failure highest and pre-failure lowest CD4 and RNA, binary indicator of clinic, and 








Figure 2: Hazard ratio of each switching delay duration subgroup vs no switch using IPW of MSM. 
a) Main analysis – Baseline: confirmed failure (Second VL>1000) 
 
b) Secondary analysis – Baseline: First VL>1000 
 
Duration of switching delay: Strategy 0: no switch (reference category), Strategy 1: Less than 30 days, Strategy 2: Greater than or equal to 30 and less than 60 days, 
Strategy 3: Greater than or equal to 60 and less than 120 days, Strategy 4: Greater than or equal to 120 and less than 180 days, Strategy 5: Greater than or equal to 180 
and less than 360 days, Strategy 6: Greater than or equal to 360 days 
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Figure 3: Probability of death 5 years after virologic failure, for different CD4 count categories at time of failure, and 
depending on month of switch (i.e. extent of delay). Estimates are based ‘on working MSM’s estimated with LTMLE as 
specified under the footnote*. 
 
*Footnote: Model specifications of the marginal structural working model. The working MSM’s specify the assumed relationship 
between the probability of death and follow-up time (t), switch time (st) and CD4 count at failure (CD4). 
Model 1: Irrespective of CD4 count: logit(P(Death(t)st)) = b0 + b1 log(t) + b2 (st-t) + b3 ([st-t]2) + b4 ([st-t]3) + b5 (log(t) * [st-t]) + b6 (log(t) * 
[st-t]2)  
Model 2: Conditional on CD4 count: logit(P(Death(t) st|CD4)) = b0 + b1 log(t) + b2 (st-t) + b3 ([st-t]2) + b4 ([st-t]3) + b5 (log(t) * [st-t]) + b6 
I(101<CD4<200) + b7 I(CD4>200) + b8 I(101<CD4<200)*(st-t)+ b9 I(CD4>200)*(st-t) + b10 I(CD4<100)*√t + b11 I(101<CD4<200) *√t + b12 
I(CD4>200)* √t 
Note that the causal quantity of interest is defined as a projection of the true causal dose–response curve, i.e. the true relationship 
between time/switch time and mortality, onto the specified working model. The working model has been specified as flexible as 
possible though computational and numerical constraints make an even more flexible approach unfeasible to estimate. 
 
